{"nctId":"NCT02005562","briefTitle":"OPERA Study: A Study of Two Dosing Regimens of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients.","startDateStruct":{"date":"2006-05"},"conditions":["Kidney Transplantation"],"count":252,"armGroups":[{"label":"Mycophenolate Mofetil, Adapted Dose","type":"EXPERIMENTAL","interventionNames":["Drug: mycophenolate mofetil","Drug: anti-IL-2R","Drug: methylprednisolone","Drug: cyclosporine"]},{"label":"Mycophenolate Mofetil, Fixed Dose","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: mycophenolate mofetil","Drug: anti-IL-2R","Drug: methylprednisolone","Drug: cyclosporine"]}],"interventions":[{"name":"mycophenolate mofetil","otherNames":["CellCept"]},{"name":"mycophenolate mofetil","otherNames":["CellCept"]},{"name":"anti-IL-2R","otherNames":[]},{"name":"methylprednisolone","otherNames":["Solumedrol"]},{"name":"cyclosporine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* adult patients, aged 18-75 years of age;\n* in receipt of first donor kidney;\n* eligible to receive immunosuppressive treatment comprising IRL2, CellCept, cyclosporine and steroids;\n* eligible to receive oral treatment from the first day post-transplantation.\n\nExclusion Criteria:\n\n* patients receiving a second or subsequent kidney transplant, or multi-organ transplant;\n* history of malignancy in the last 5 years (except successfully treated squamous cell or basal cell cancer and cervical cancer in situ);\n* patients with active hepatitis B and/or hepatitis C, or HIV infection.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Biopsy-Proven Acute Rejection (BPAR) Before Week 12 or Acute Subclinical Rejection on Protocol Biopsy at Week 12","description":"BPAR was defined as the presence of clinical signs and kidney biopsy that confirmed the rejection before Week 12. Subclinical acute rejection was defined as an increase of serum creatinine at Week 12 strictly less than 10 percent (%) compared to baseline (BL) values and BPAR of Grade greater than or equal to (≥) 1 according to Banff 1997 classification at Week 12.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.2","spread":null},{"groupId":"OG001","value":"19.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum Creatinine Values [Micromoles Per Liter (µmol/L)]","description":"The mean serum creatinine values at Weeks 2, 4, 6, 12, 16, 26, 39, and 52.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"202.41","spread":"144.80"},{"groupId":"OG001","value":"201.31","spread":"130.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"168.92","spread":"95.66"},{"groupId":"OG001","value":"174.86","spread":"77.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"155.74","spread":"84.01"},{"groupId":"OG001","value":"158.96","spread":"59.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"140.80","spread":"53.18"},{"groupId":"OG001","value":"147.70","spread":"50.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"145.48","spread":"83.00"},{"groupId":"OG001","value":"148.48","spread":"71.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"131.73","spread":"42.20"},{"groupId":"OG001","value":"143.73","spread":"46.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"136.24","spread":"45.84"},{"groupId":"OG001","value":"141.89","spread":"47.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"148.62","spread":"124.30"},{"groupId":"OG001","value":"144.72","spread":"47.37"}]}]}]},{"type":"SECONDARY","title":"Creatinine Clearance Values Estimated With the Cockcroft-Gault Equation (Milliliters Per Minute [mL/Min])","description":"The mean creatinine clearance values at Weeks 2, 4, 6, 12, 16, 26, 39, and 52 estimated using the Cockcroft-Gault equation.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.68","spread":"21.05"},{"groupId":"OG001","value":"45.26","spread":"18.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.03","spread":"19.17"},{"groupId":"OG001","value":"46.73","spread":"18.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.66","spread":"20.94"},{"groupId":"OG001","value":"49.77","spread":"19.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.55","spread":"19.40"},{"groupId":"OG001","value":"53.01","spread":"20.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.55","spread":"20.14"},{"groupId":"OG001","value":"53.49","spread":"19.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.21","spread":"21.35"},{"groupId":"OG001","value":"55.18","spread":"20.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.17","spread":"19.86"},{"groupId":"OG001","value":"56.81","spread":"21.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.29","spread":"20.42"},{"groupId":"OG001","value":"56.45","spread":"22.02"}]}]}]},{"type":"SECONDARY","title":"Creatinine Clearance Values Estimated With the Modification of Diet in Renal Disease (MDRD) Simplified Equation","description":"The mean creatinine clearance values at Weeks 2, 4, 6, 12, 16, 26, 39, and 52 estimated using the MDRD simplified equation. For males, the MDRD simplified equation was defined as MDRD (mL/min/1.73 square meters \\[m\\^2\\]) =186 multiplied by (\\*) serum creatinine in mg/L raised to the power of (\\^) -1.154 \\* age \\^ -0.203. For females, the MDRD simplified equation was defined as MDRD (mL/min/1.73 m\\^2) = males formula \\* 0.742.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.61","spread":"19.00"},{"groupId":"OG001","value":"39.60","spread":"18.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.02","spread":"16.58"},{"groupId":"OG001","value":"41.31","spread":"16.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.12","spread":"19.32"},{"groupId":"OG001","value":"44.69","spread":"16.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.93","spread":"16.27"},{"groupId":"OG001","value":"47.68","spread":"16.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.93","spread":"17.05"},{"groupId":"OG001","value":"48.52","spread":"17.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.22","spread":"16.76"},{"groupId":"OG001","value":"49.46","spread":"18.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.23","spread":"15.94"},{"groupId":"OG001","value":"50.01","spread":"18.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.82","spread":"16.33"},{"groupId":"OG001","value":"48.88","spread":"18.24"}]}]}]},{"type":"SECONDARY","title":"Time to Occurrence of First BPAR Between Day 0 and Week 52 - Percentage of Participants With an Event","description":"BPAR was defined as the presence of clinical signs and kidney biopsy that confirmed the rejection before Week 12. Subclinical acute rejection at Week 12 was included in the analysis. Subclinical acute rejection was defined as an increase of serum creatinine at Week 12 strictly less than 10% compared to BL values and BPAR of Grade ≥1 according to Banff 1997 classification at Week 12. The occurrence of the first BPAR was defined as the time from randomization to the first recorded BPAR between Day 0 and Week 52. The results of protocol biopsies at Week 12 were taken into account. Participants were censored at the date of last treatment, date of last contact or withdrawal, and date of death.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.6","spread":null},{"groupId":"OG001","value":"14.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Occurrence of First BPAR Between Day 0 and Week 52","description":"BPAR was defined as the presence of clinical signs and kidney biopsy that confirmed the rejection before Week 12. Subclinical acute rejection at Week 12 was included in the analysis. Subclinical acute rejection was defined as an increase of serum creatinine at Week 12 strictly less than 10% compared to BL values and BPAR of Grade ≥1 according to Banff 1997 classification at Week 12. The occurrence of the first BPAR was defined as the time from randomization to the first recorded BPAR between Day 0 and Week 52. The results of protocol biopsies at Week 12 were taken into account. Participants were censored at the date of last treatment, date of last contact or withdrawal, and date of death.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With at Least One BPAR at Week 12 and Week 52","description":"BPAR was defined as the presence of clinical signs and kidney biopsy that confirmed the rejection before Week 12. Participants were censored at the date of last treatment, date of last contact or withdrawal, and date of death.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.1","spread":null},{"groupId":"OG001","value":"10.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.1","spread":null},{"groupId":"OG001","value":"10.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Graft Histology - Percentage of Participants With at Least One Borderline Lesion at Week 12 and Week 52","description":"Participants were censored at the date of last treatment, date of last contact or withdrawal, and date of death.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.9","spread":null},{"groupId":"OG001","value":"12.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.4","spread":null},{"groupId":"OG001","value":"5.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Graft Histology - Percentage of Participants With at Least One Chronic Graft Nephropathy at Week 12 and Week 52","description":"Participants were censored at the date of last treatment, date of last contact or withdrawal, and date of death.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.6","spread":null},{"groupId":"OG001","value":"17.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.5","spread":null},{"groupId":"OG001","value":"34.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Graft Loss - Percentage of Participants With an Event","description":"Graft loss was defined as physical loss (nephrectomy), functional loss \\[necessitating maintenance dialysis for greater than (\\>)8 weeks\\], retransplant or death. Participants were censored at the date of last treatment, date of last contact or withdrawal, and date of death.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":null},{"groupId":"OG001","value":"5.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Graft Loss","description":"The median time, in days, from randomization to graft loss event. Participants were censored at the date of last treatment, date of last contact or withdrawal, and date of death.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"},{"groupId":"OG001","value":"NA","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Participant Survival","description":"Participants survival was defined as the percentage of participants living with or without a functioning graft between Weeks 0 and 52. Participants were censored at the date of last treatment, date of last contact or withdrawal, and date of death.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.4","spread":null},{"groupId":"OG001","value":"98.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":106,"n":127},"commonTop":["Anaemia","Leukopenia","Urinary tract infection","Oedema peripheral","Hypertension"]}}}